Multiple Myeloma and Osteoporosis: How Bone Damage from Cancer Worsens Fracture Risk

The Dual Bone Threat

Multiple myeloma (MM) and osteoporosis both weaken bone—but through distinct, synergistic mechanisms. MM patients have 2–4× higher fracture risk than age-matched controls, even after adjusting for bone density.

How Myeloma Destroys Bone

  1. RANKL/OPG dysregulation: Myeloma cells and stromal cells overexpress RANKL, suppress OPG → uncontrolled osteoclast activation → lytic lesions
  2. Osteoblast suppression: DKK1, sclerostin, IL-3, TNF-α inhibit bone formation → "uncoupled" remodeling (resorption without repair)
  3. Direct tumor invasion: Marrow replacement, cortical destruction
  4. Renal impairment: Reduced 1,25-vitamin D synthesis → secondary hyperparathyroidism → bone resorption
  5. Hypogonadism: Common in men with MM; accelerates bone loss
  6. Glucocorticoids (dexamethasone): Backbone of MM regimens; direct osteoblast toxicity, reduced calcium absorption, increased excretion

Osteoporosis Compounds the Risk

  • Age-related bone loss + MM bone disease = additive fragility
  • Vertebral compression fractures (VCFs) cause kyphosis, height loss, chronic pain, respiratory compromise
  • Femoral neck fractures → loss of independence, mortality

Bone-Directed Therapy: Standard of Care

AgentDosingKey Points
Zoledronic acid (Zometa)4 mg IV q4wks (adjust for CrCl); load q3–4mo after 1–2 yrs if stableReduces SREs by 30–40%; renal monitoring required; ONJ risk ~1–2%
Denosumab (Xgeva)120 mg SC q4wks + Ca/Vit DNon-inferior to zoledronic for SREs; no renal adjustment; ONJ similar; hypocalcemia risk; rebound vertebral fractures on discontinuation → transition to bisphosphonate

Start at diagnosis for all MM with bone involvement (lytic lesions, osteoporosis, fracture). Continue indefinitely while on active therapy.

Comprehensive Bone Health Strategy

  • Baseline: DEXA (spine/hip), lateral spine X-rays (VFA for occult VCFs), Ca, 25-OH-D, PTH, bone turnover markers (CTX, P1NP)
  • Calcium: 1200 mg/day total (diet + supplement); citrate preferred if on PPI
  • Vitamin D: Target 25-OH-D 40–60 ng/mL (higher than general population)
  • Exercise: Weight-bearing + resistance 3×/week; balance training; avoid spinal flexion (VCF risk)
  • Fall prevention: Home safety, vision check, medication review, hip protectors if high risk
  • Lifestyle: Smoking cessation, alcohol moderation
  • Monitoring: DEXA q1–2 yrs; height measurement annually; clinical fracture assessment

Vertebral Fracture Management

  • Acute: Analgesia, brief rest, early mobilization, bracing (controversial)
  • Kyphoplasty/vertebroplasty: Consider for refractory pain; cement leakage risk in lytic lesions
  • Radiation: For painful lytic lesions/plasmacytomas (8 Gy × 1 or 20 Gy/5)

Bone health is not ancillary in myeloma—it's central to survival and quality of life. Integrate bone-directed therapy from day one and maintain vigilance throughout the disease course.

Osteoporosis - Related Articles